Cofactor Genomics

St. Louis-based Cofactor will use the National Cancer Institute's clinical specimens in order to validate its Paragon assay platform.

Researchers who used the company's service presented data this week from analyses of sarcoma patients that they believe can help personalize care.

The financing follows Cofactor's launch of Pinnacle, an RNA-based oncology assay and the company's first product since a strategic refocusing.

The Pinnacle assay for gene fusions and gene expression in tumor samples is the first in Cofactor's new line of clinical RNA-sequencing assays.

The platform will be designed to gather all necessary data from a single RNA extraction, eliminating the need for flow cytometry, genomic sequencing, and expression profiling.

The companies will combine Cofactor's RNA-seq know-how with SII's big data analytics offerings to provide services for pharmaceutical research customers.

The RNA products developer is buying California-based Narus in order to expand into the RNA-based diagnostics market.

The company aims to use the funding to further optimize the technology and support an ongoing early-access program with beta testers.

The firm was named a certified service provider for Agilent's SureSelect Methyl-Seq target enrichment.

NEW YORK (GenomeWeb) – Cofactor Genomics said on Thursday it has won a contract from the National Heart, Lung, and Blood Institute and the National Human Genome Research Institute to identify sites of epigenetic modifications that contribute to cardiovascular disease endpoints.

Pages

The UK's Nuffield Council on Bioethics says genetically modifying human embryos could be morally permissible, according to the Guardian.

A new Nature Biotechnology paper reports that CRISPR-Cas9 gene editing can lead to large deletions or complex rearrangements that could be pathogenic.

The Wall Street Journal likens a prototype developed by Synthetic Genomics to a "biological fax machine."

In PNAS this week: strategy for reactivating Rett syndrome-linked MECP2, small molecules able to suppress Staphylococcus aureus virulence, and more.